Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
This study, called a Phase 2 trial, is looking at a new medicine called Anumigilimab for adults living with sickle cell disease. The main goal is to check how safe Anumigilimab is when given under the skin. Some participants will receive the active medicine, while others will get a placebo (a dummy medicine without any active ingredients). This helps researchers understand the medicine's true effects. The study will last for 64 weeks, which is about 15 months. During this time, the dose of Anumigilimab will be slowly increased to find the best tolerated amount, and then participants will continue on that dose. This research is important for finding new ways to manage sickle cell disease.
A colpo d'occhio
Di cosa tratta questo studio?
This study is a Phase 2 trial, which means it's an early but important step in developing new medicines. For adults with sickle cell disease, researchers are looking at a new drug called Anumigilimab. The main purpose of this study is to carefully check if Anumigilimab is safe for people with sickle cell disease. It's designed to be a thorough investigation into any potential side effects.
Participants will be given the study medicine, or a placebo (an inactive substance that looks just like the study medicine), as an injection under the skin. This approach helps researchers to accurately compare the effects of the new medicine against no active treatment, without anyone knowing who is receiving which, until the study is over. The study will last for a total of 64 weeks, which is a bit over a year. During the first 12 weeks, the dose of the medicine will be gradually increased to find the highest amount that each person can comfortably take. After this, participants will continue on that dose for the remaining 52 weeks.
Finding new, safe, and effective treatments for sickle cell disease is really important for improving the lives of those affected. Studies like this help us understand if new medicines could be a good option for the future. By carefully observing participants and gathering information on how they respond to Anumigilimab, researchers hope to learn more about its potential role in managing sickle cell disease.
Punti chiave
- This study is testing a new medicine called Anumigilimab for sickle cell disease.
- The main goal is to check how safe the medicine is.
- Participants will receive the medicine or a placebo as an injection under the skin.
- The study lasts for 64 weeks (about 15 months).
- It's for adults aged 18 and over with sickle cell disease who have experienced pain crises.
- This research is an important step in finding new treatments for sickle cell disease.
Chi può essere idoneo?
To join this study, you need to be an adult, aged 18 or older, and have a confirmed diagnosis of sickle cell disease, no matter your specific type. You should also have experienced a certain number of pain crises (called VOCs) in the past year that required medical help and strong pain relief.
You might be taking a medicine called Hydroxyurea (HU) – if so, you need to have been on a stable dose for at least a month. If you've stopped taking HU, or if it wasn't right for you, you might still be able to join. Your doctor will check if you meet all the health requirements to ensure the study is safe for you.
There are also a few reasons why someone might not be able to join. For example, if your white blood cell count (a type of blood cell) is too low, or if you've recently changed your dose of other sickle cell preventive medicines, you might not be eligible. These rules are in place to keep everyone safe and make sure the study results are clear.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Do you have a confirmed diagnosis of sickle cell disease?
- Have you had 1 to 12 pain crises (VOCs) that needed medical help in the last year?
- Are you on a stable dose of Hydroxyurea for at least 30 days, or have you stopped/refused it?
- Do you have a healthy enough white blood cell count (neutrophils)?
- Have you been on a stable dose of any other sickle cell preventive medicines for at least 30 days?
Cosa comporta la partecipazione?
If you join this study, you will be in it for a total of 64 weeks, which is about 15 months. For the first 12 weeks, you'll have regular visits where the dose of the study medicine will be slowly increased to find the best amount for you. After that, you'll continue on that dose for the remaining 52 weeks.
Throughout the study, you'll receive the medicine (either Anumigilimab or a placebo) as an injection under your skin. You'll have regular check-ups with the study team. These visits will involve various tests and assessments, such as blood tests, to monitor your health and see how you are responding to the treatment. The research team will explain the full schedule of visits and what each visit will involve in detail.
Rischi e benefici potenziali
Luoghi (38)
- UAMS Medical CenterCodice postale verificatoLittle Rock, Stati Uniti· Reclutamento
- University of California IrvineCodice postale verificatoOrange, Stati Uniti· Reclutamento
- The Foundation for Sickle Cell DiseaseCodice postale verificatoHollywood, Stati Uniti· Reclutamento
- Arthur M. Blank Hospital- Children's Healthcare of AtlantaCodice postale verificatoAtlanta, Stati Uniti· Reclutamento
- Center for Cancer and Blood DisordersCodice postale verificatoBethesda, Stati Uniti· Reclutamento
- Boston Medical CenterCodice postale verificatoBoston, Stati Uniti· Reclutamento
- University of MinnesotaCodice postale verificatoMinneapolis, Stati Uniti· Reclutamento
- Southern Specialty ResearchCodice postale verificatoFlowood, United States· Reclutamento
- NYC Health + Hospitals/QueensCodice postale verificatoJamaica, United States· Reclutamento
- Columbia University Medical CenterCodice postale verificatoNew York, Stati Uniti· Reclutamento
- Jacobi Medical CenterCodice postale verificatoIl Bronx, Stati Uniti· Reclutamento
- Ohio State UniversityCodice postale verificatoColumbus, Stati Uniti· Reclutamento
Domande comuni
What is Anumigilimab?
Anumigilimab is an investigational medicine being studied for sickle cell disease. It's not yet approved for general use.
What is a 'placebo'?
A placebo is a dummy medicine that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the new drug.
Why is this called a 'Phase 2' study?
Phase 2 studies are an early stage of research focusing on finding the right dose and further checking the safety of a new medicine in a larger group of people.
Will I know if I'm getting the actual medicine or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you're receiving Anumigilimab or the placebo until the study ends.
Come verrà somministrato il medicinale?
The study medicine will be given as an injection under the skin.
Come saperne di più
Trial Registration Coordinator
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.